Specialty Pharmacy

CMS report shows spending rates are lower compared with the years prior to health care reform.

Treatment shows clinically meaningful reduction in the number of cancer cells in patients with relapsed or refractory chronic lymphocytic leukemia.

MS patients with visual problems perform worse in testing than patients without visual problems but with MS.

Higher number of unprotected sexual encounters correlates with enhanced cell expressions.

Early treatment found to be cost-effective compared with waiting until liver fibrosis worsens.

Overall survival rate nearly doubles in patients who used aspirin post-diagnosis.

Addition of midostaurin to chemotherapy shows promise in patients with AML.

Successful response to hepatitis C treatment shows a 30 percent increased reduction in liver stiffness.

Majority of hemophilia patients show problems with mobility, daily activities, and pain.

Experts provide unique perspectives on the safety, efficacy, and potential for clinical integration of 3 recently approved agents for multiple myeloma.

Rare disease can cause serious liver and cardiovascular conditions.

Addition of bortezomib to lenalidomide and low-dose dexamethasone therapy extends disease control.

Researchers determine how the liver is able to naturally inhibit HCV infection.

Scientists discover threat from AAV2 virus and from correlation to the development of liver cancer.

Recent case reports indicate possible anti-lymphoma efficacy of direct-acting antivirals in patients with both lymphoma and hepatitis C.

Anemia caused by chemotherapy for lymphoid malignancies improved in patients with non-Hodgkin's lymphoma and multiple myeloma.

Warnings about the risk of ketoacidosis and serious urinary tract infections have been added to the labels of SGLT2 inhibitors.

Potentially game changing drug may alter diabetes disease course.

David Lassen, chief clinical officer at Prime Therapeutics, discusses implications for specialty pharmacy from health care reform.

Recent case reports indicate possible anti-lymphoma efficacy of direct-acting antivirals in patients with both lymphoma and hepatitis C.

Researchers perform deeper analysis of recombinant factor VIII Fc fusion protein.

Epoetin alfa biosimilar shows promise in early study.

Pollutants may accelerate fibrosis, metabolic disease, and liver cancer.

Treatment with bevacizumab and lomustine not found to offer a survival advantage.

Top recent news in cancer drug development.

NS3 enzyme interacts with RNA and helps the pathogen replication process.

Chemosensitivity, treatment variations, and socioeconomic factors may be a significant factor.

Excess production of tumor necrosis factor causes both RA and the onset of heart valve disease.